Latest Clinical Development News

Page 15 of 57
Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.
Ada Torres
Ada Torres
29 Apr 2026
Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.
Ada Torres
Ada Torres
29 Apr 2026
Resonance Health reports strong cash flow and progress in clinical trials, with a record forward order pipeline for its Software-as-a-Medical-Device business and profitable trial site clinics.
Ada Torres
Ada Torres
29 Apr 2026
Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.
Ada Torres
Ada Torres
29 Apr 2026
TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.
Ada Torres
Ada Torres
29 Apr 2026
AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.
Ada Torres
Ada Torres
29 Apr 2026
Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.
Ada Torres
Ada Torres
29 Apr 2026
Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.
Ada Torres
Ada Torres
28 Apr 2026
Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.
Ada Torres
Ada Torres
28 Apr 2026
PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.
Ada Torres
Ada Torres
28 Apr 2026
Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.
Ada Torres
Ada Torres
28 Apr 2026
LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.
Ada Torres
Ada Torres
28 Apr 2026

Browse the archive

Full archive